Prescription Description
| Prescription ID | TCMF4097 |
| Pinyin Name | Hai Long Jiao |
| Chinese Name | 海龙胶 |
| English Name | Hai Long Jiao |
| Function Description | 阳痿, 遗精, 不孕 |
| Indications | Involuntary ejaculation disorder, Impotence disorder, Infertility disorder, Infertility, Sexual dysfunction |
| Disease ICD-11 Category |
SB09 [Involuntary ejaculation disorder (TM1), 遗精 (TM1)
]; SB0B [Impotence disorder (TM1), 阳痿 (TM1) ]; SC22 [Infertility disorder (TM1), 不孕 (TM1) ]; GA31 [Female infertility, 女性不孕症 ]; HA0Z [Sexual dysfunctions, unspecified, 性功能障碍，未特指的 ]; |
| Human Tissues Associated with Indication | Kidney |
| Reference | CFDA |
| Reference Book/link | http://samr.cfda.gov.cn/WS01/CL0001/ |
Prescription Components
| Component ID | Latin Name | Chinese Name | Component Quantity | Barcode |
|---|---|---|---|---|
| TCMH784 | Syngnathus sp. | 海龙 | TCMH784 | FBERM005-06 |
| TCMH979 | Bos taurus domesticus | 黄明胶 | TCMH979 | |
| TCMH421 | Angelica sinensis | 当归 | TCMH421 | ITSAF173-14 |
| TCMH305 | Cnidium officinale | 川芎 | TCMH305 | ITSAP4207-14 |
| TCMH1740 | Cistanche deserticola | 肉苁蓉 | TCMH1740 | ITSAM2511-14 |
| TCMH981 | Astragalus membranaceus | 黄芪 | TCMH981 | ITSAK2981-14 |
| TCMH104 | Paeonia lactiflora | 白芍 | TCMH104 | ITSAH2416-14 |
| TCMH1742 | Cinnamomum cassia | 肉桂 | TCMH1742 | GQ255631 |
| TCMH1186 | Lycium chinense | 枸杞子 | TCMH1186 | ITSAO4545-14 |
| TCMH243 | Pericarpium citri reticulatae | 陈皮 | TCMH243 | |
| TCMH628 | Glycyrrhiza uralensis | 甘草 | TCMH628 | ITSAM892-14 |
Targeted Human Proteins by the Ingredients of Prescription
| Target ID | Gene Symbol | Target Name | Target Class | Uniprot ID |
|---|---|---|---|---|
| TCMT101 | PTPN1 | Protein-tyrosine phosphatase 1B | Hydrolase | P18031 |
| TCMT112 | ADORA3 | Adenosine A3 receptor | GPCR | P0DMS8 |
| TCMT127 | PARP1 | Poly [ADP-ribose] polymerase-1 | Transferase | P09874 |
| TCMT128 | TNKS2 | Tankyrase-2 | Transferase | Q9H2K2 |
| TCMT129 | TNKS | Tankyrase-1 | Transferase | O95271 |
| TCMT131 | ACHE | Acetylcholinesterase | Hydrolase | P22303 |
| TCMT133 | CA1 | Carbonic anhydrase I | Lyase | P00915 |
| TCMT134 | CA2 | Carbonic anhydrase II | Lyase | P00918 |
| TCMT135 | CA14 | Carbonic anhydrase XIV | Lyase | Q9ULX7 |
| TCMT136 | CA12 | Carbonic anhydrase XII | Lyase | O43570 |
| TCMT137 | CA9 | Carbonic anhydrase IX | Lyase | Q16790 |
| TCMT138 | CA7 | Carbonic anhydrase VII | Lyase | P43166 |
| TCMT139 | CA6 | Carbonic anhydrase VI | Lyase | P23280 |
| TCMT140 | CA5B | Carbonic anhydrase VB | Lyase | Q9Y2D0 |
| TCMT141 | CA5A | Carbonic anhydrase VA | Lyase | P35218 |
| TCMT142 | CA4 | Carbonic anhydrase IV | Lyase | P22748 |
| TCMT156 | CYP19A1 | Cytochrome P450 19A1 | Oxidoreductase | P11511 |
| TCMT159 | TYR | Tyrosinase | Oxidoreductase | P14679 |
| TCMT161 | HCAR2 | Hydroxycarboxylic acid receptor 2 | GPCR | Q8TDS4 |
| TCMT162 | UGT1A1 | UDP-glucuronosyltransferase 1-1 | Transferase | P22309 |
| TCMT174 | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | Oxidoreductase | P28845 |
| TCMT190 | PTPN2 | T-cell protein-tyrosine phosphatase | Hydrolase | P17706 |
| TCMT206 | CYP2A6 | Cytochrome P450 2A6 | Oxidoreductase | P11509 |
| TCMT209 | HSD11B2 | 11-beta-hydroxysteroid dehydrogenase 2 | Oxidoreductase | P80365 |
| TCMT215 | CYP1A1 | Cytochrome P450 1A1 | Oxidoreductase | P04798 |
| TCMT219 | CYP1A2 | Cytochrome P450 1A2 | Oxidoreductase | P05177 |
| TCMT223 | AKR1B1 | Aldose reductase | Oxidoreductase | P15121 |
| TCMT23 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Hydrolase | P05186 |
| TCMT231 | GBA2 | Beta-glucosidase | Hydrolase | Q9HCG7 |
| TCMT236 | ESR2 | Estrogen receptor beta | Nuclear receptor | Q92731 |
| TCMT249 | CDK6 | Cyclin-dependent kinase 6 | Kinase | Q00534 |
| TCMT257 | CYP1B1 | Cytochrome P450 1B1 | Oxidoreductase | Q16678 |
| TCMT261 | DAPK1 | Death-associated protein kinase 1 | Kinase | P53355 |
| TCMT268 | CYP2A13 | Cytochrome P450 2A13 | Oxidoreductase | Q16696 |
| TCMT280 | AKR1B10 | Aldo-keto reductase family 1 member B10 | Oxidoreductase | O60218 |
| TCMT290 | CHRM5 | Muscarinic acetylcholine receptor M5 | GPCR | P08912 |
| TCMT291 | CHRM3 | Muscarinic acetylcholine receptor M3 | GPCR | P20309 |
| TCMT292 | CHRM1 | Muscarinic acetylcholine receptor M1 | GPCR | P11229 |
| TCMT293 | CHRM2 | Muscarinic acetylcholine receptor M2 | GPCR | P08172 |
| TCMT295 | MMP1 | Matrix metalloproteinase-1 | Hydrolase | P03956 |
| TCMT296 | ADORA1 | Adenosine A1 receptor | GPCR | P30542 |
| TCMT297 | FABP4 | Fatty acid binding protein adipocyte | Unclassified | P15090 |
| TCMT298 | FABP3 | Fatty acid binding protein muscle | Hydrolase | P05413 |
| TCMT306 | MMP2 | Matrix metalloproteinase-2 | Hydrolase | P08253 |
| TCMT321 | MMP9 | Matrix metalloproteinase 9 | Hydrolase | P14780 |
| TCMT332 | AOC3 | Amine oxidase, copper containing | Oxidoreductase | Q16853 |
| TCMT344 | AOX1 | Aldehyde oxidase | Oxidoreductase | Q06278 |
| TCMT46 | F3 | Coagulation factor III | Unclassified | P13726 |
| TCMT47 | BCL2 | Apoptosis regulator Bcl-2 | Ion channel | P10415 |
| TCMT506 | PTK2B | Protein tyrosine kinase 2 beta | Kinase | Q14289 |
| TCMT560 | F10 | Coagulation factor X | Unclassified | P00742 |
| TCMT563 | CDC25B | Dual specificity phosphatase Cdc25B | Hydrolase | P30305 |
| TCMT591 | ESRRA | Estrogen-related receptor alpha | Nuclear receptor | P11474 |
| TCMT592 | XDH | Xanthine dehydrogenase | Oxidoreductase | P47989 |
| TCMT597 | SLC28A3 | Solute carrier family 28 member 3 | Transporter | Q9HAS3 |
| TCMT599 | UBE2N | Ubiquitin-conjugating enzyme E2 N | Transferase | P61088 |
| TCMT614 | EGLN1 | Egl nine homolog 1 | Oxidoreductase | Q9GZT9 |
| TCMT63 | PPARA | Peroxisome proliferator-activated receptor alpha | Nuclear receptor | Q07869 |
| TCMT637 | SIRT3 | NAD-dependent deacetylase sirtuin 3 | Hydrolase | Q9NTG7 |
| TCMT638 | SIRT2 | NAD-dependent deacetylase sirtuin 2 | Hydrolase | Q8IXJ6 |
| TCMT65 | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | Oxidoreductase | P14061 |
| TCMT66 | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | Oxidoreductase | P37059 |
| TCMT690 | HDAC3 | Histone deacetylase 3 | Hydrolase | O15379 |
| TCMT709 | SLC28A2 | Sodium/nucleoside cotransporter 2 | Transporter | O43868 |
| TCMT710 | SLC28A1 | Sodium/nucleoside cotransporter 1 | Transporter | O00337 |
| TCMT752 | CSNK2A1 | Casein kinase II alpha | Kinase | P68400 |
| TCMT808 | FABP5 | Fatty acid binding protein epidermal | Unclassified | Q01469 |
| TCMT809 | FABP2 | Fatty acid binding protein intestinal | Unclassified | P12104 |
| TCMT810 | TLR2 | Toll-like receptor 2 | Unclassified | O60603 |
| TCMT82 | ESR1 | Estrogen receptor alpha | Nuclear receptor | P03372 |
| TCMT822 | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Transferase | Q11130 |
| TCMT87 | CYP2C9 | Cytochrome P450 2C9 | Oxidoreductase | P11712 |
| TCMT910 | ESRRB | Estrogen-related receptor beta | Nuclear receptor | O95718 |
Targeted Pathogenic Microbes by the Ingredients of Prescription
| Target ID | Target Name |
|---|---|
| TCMT1170 | Enterobacter cloacae |
| TCMT1175 | Human immunodeficiency virus |
| TCMT1176 | Streptococcus pneumoniae |
| TCMT1178 | Actinomyces viscosus |
| TCMT1179 | Escherichia coli ATCC 8739 |
| TCMT1181 | Mycobacterium tuberculosis H37Ra |
| TCMT1186 | Plasmodium yoelii yoelii |
| TCMT1189 | Pseudomonas fluorescens |
| TCMT1190 | Plasmodium falciparum (isolate FcB1 / Columbia) |
| TCMT1209 | Staphylococcus haemolyticus |
| TCMT1210 | Streptococcus sobrinus |
| TCMT1211 | Fusobacterium nucleatum |
| TCMT1212 | Verticillium dahliae |
| TCMT1214 | Enterococcus faecium |
| TCMT1215 | Pseudomonas aeruginosa PAO1 |
| TCMT1218 | Staphylococcus aureus |
| TCMT1221 | Human herpesvirus 4 |
| TCMT1222 | Plasmodium falciparum D6 |
| TCMT1223 | Staphylococcus epidermidis |
| TCMT1224 | Proteus mirabilis |
| TCMT1226 | Klebsiella pneumoniae |
| TCMT1227 | Streptococcus |
| TCMT1229 | Enterococcus faecalis |
| TCMT1232 | Pseudomonas aeruginosa |
| TCMT1234 | Bacillus coagulans |
| TCMT1235 | Clostridium sporogenes |
| TCMT1236 | Mycobacterium bovis |
| TCMT1237 | Mycobacterium kansasii |
| TCMT1238 | Mycobacterium xenopi |
| TCMT1239 | Mycobacterium marinum |
| TCMT1243 | Aspergillus flavus |
| TCMT1245 | Phytophthora cactorum |
| TCMT1246 | Escherichia coli |
| TCMT1248 | Hepatitis C virus |
| TCMT1249 | Dengue virus 2 |
| TCMT1251 | Candida albicans |
| TCMT1253 | Penicillium chrysogenum |
| TCMT1255 | Human immunodeficiency virus 1 |
| TCMT1284 | Penicillium expansum |
| TCMT1286 | Bacillus cereus |
| TCMT1294 | Human parainfluenza virus 3 |
| TCMT1318 | Human T-lymphotropic virus 1 |
| TCMT1321 | Staphylococcus hominis |
| TCMT1343 | Staphylococcus simulans |
| TCMT1344 | Staphylococcus sciuri |
| TCMT1346 | Helicobacter pylori |
| TCMT1349 | Helicobacter pylori SS1 |
| TCMT1361 | Neisseria meningitidis |
| TCMT1370 | Prevotella melaninogenica |
| TCMT1382 | Plasmodium falciparum (isolate K1 / Thailand) |
| TCMT1408 | Colletotrichum gloeosporioides |
| TCMT1412 | Salmonella typhimurium |
| TCMT1438 | Plasmodium falciparum |
| TCMT1439 | Mycobacterium smegmatis |
| TCMT1442 | Leishmania donovani |
| TCMT1443 | Leishmania amazonensis |
| TCMT1444 | Fusarium oxysporum |
| TCMT1447 | Respiratory syncytial virus |
| TCMT1448 | Enterobacter aerogenes |
| TCMT1449 | Influenza A virus |
| TCMT1450 | Plasmodium falciparum 3D7 |
| TCMT1454 | Bacillus subtilis |
| TCMT1455 | Mycobacterium tuberculosis H37Rv |
| TCMT1457 | Leishmania major |
| TCMT1458 | Filobasidiella neoformans |
| TCMT1462 | Streptococcus mutans |
| TCMT1463 | Mycobacterium tuberculosis |
| TCMT1464 | Hepatitis B virus |
| TCMT1465 | Entamoeba histolytica |
Gene Ontology Associated to Targeted Human Proteins
| GO Term | GO Name | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|---|
| [BP] GO:0015701 | bicarbonate transport | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 12.6081 |
| [BP] GO:0006730 | one-carbon metabolic process | CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 11.6217 |
| [BP] GO:0019748 | secondary metabolic process | AKR1B1, AKR1B10, BCL2, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, TYR | 10.2724 |
| [BP] GO:0008202 | steroid metabolic process | AKR1B1, AKR1B10, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, ESR1, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 9.41063 |
| [BP] GO:0006629 | lipid metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, ESR1, FABP3, FABP4, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PPARA | 8.00892 |
| [BP] GO:0044281 | small molecule metabolic process | AKR1B1, AKR1B10, AOX1, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, FABP3, FUT7, GBA2, PPARA, TYR, XDH | 7.80881 |
| [BP] GO:0042445 | hormone metabolic process | ACHE, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 6.8276 |
| [BP] GO:0008152 | metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CDC25B, CDK6, CHRM1, CHRM3, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, ESR1, ESR2, ESRRA, ESRRB, F10, F3, FABP3, FABP4, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MMP1, MMP2, MMP9, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 6.51755 |
| [BP] GO:0007197 | None | CHRM1, CHRM2, CHRM3, CHRM5 | 6.47324 |
| [BP] GO:0007207 | None | CHRM1, CHRM2, CHRM3, CHRM5 | 6.0405 |
| [BP] GO:0015711 | organic anion transport | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, FABP3, PPARA | 5.79173 |
| [BP] GO:0019373 | epoxygenase P450 pathway | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 5.5752 |
| [BP] GO:1901700 | response to oxygen-containing compound | AKR1B1, ALPL, BCL2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, HSD11B2, HSD17B2, MMP2, MMP9, PPARA, TYR | 5.21968 |
| [BP] GO:0033993 | response to lipid | ALPL, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, ESR1, ESRRA, FABP3, HSD11B2, HSD17B2, TYR | 5.15544 |
| [BP] GO:0010817 | regulation of hormone levels | ACHE, ADORA1, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HCAR2, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 4.96504 |
| [BP] GO:0055114 | oxidation-reduction process | AKR1B1, AKR1B10, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TYR, XDH | 4.90274 |
| [BP] GO:0042446 | hormone biosynthetic process | AKR1B1, CYP19A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 4.89663 |
| [BP] GO:0034754 | cellular hormone metabolic process | AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD17B1, HSD17B2 | 4.84751 |
| [BP] GO:0006820 | anion transport | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, FABP3, PPARA | 4.70283 |
| [BP] GO:0065008 | regulation of biological quality | ACHE, ADORA1, AKR1B1, BCL2, CA12, CA2, CA7, CDK6, CHRM1, CHRM3, CYP19A1, CYP1A1, CYP1B1, ESR1, F10, F3, FABP3, FABP4, HCAR2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PPARA, TNKS, TNKS2, XDH | 4.42477 |
| [BP] GO:0044237 | cellular metabolic process | ACHE, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CDC25B, CDK6, CHRM1, CHRM3, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, ESR1, ESR2, ESRRA, ESRRB, F10, FABP3, FABP4, FUT7, GBA2, HSD17B1, HSD17B2, MMP1, MMP2, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 4.36478 |
| [BP] GO:0032847 | regulation of cellular pH reduction | BCL2, CA2, CA7 | 4.31258 |
| [BP] GO:0007213 | None | CHRM1, CHRM2, CHRM3, CHRM5 | 4.24555 |
| [BP] GO:0009725 | response to hormone | AKR1B1, ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A2, ESR1, ESRRA, FABP3, HSD11B2, PPARA | 3.89517 |
| [BP] GO:0019369 | arachidonic acid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 3.69795 |
| [BP] GO:0095500 | None | CHRM1, CHRM2, CHRM3, CHRM5 | 3.66177 |
| [BP] GO:1903831 | None | CHRM1, CHRM2, CHRM3, CHRM5 | 3.66177 |
| [BP] GO:0008210 | estrogen metabolic process | CYP19A1, CYP1B1, HSD17B1, HSD17B2 | 3.5921 |
| [BP] GO:0014070 | response to organic cyclic compound | ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, HSD11B2, TYR | 3.5225 |
| [BP] GO:0009698 | phenylpropanoid metabolic process | CYP1A1, CYP2A13, CYP2A6 | 3.5225 |
| [BP] GO:0009804 | coumarin metabolic process | CYP1A1, CYP2A13, CYP2A6 | 3.5225 |
| [BP] GO:0016042 | lipid catabolic process | ADORA1, AKR1B10, CYP19A1, CYP1A2, CYP1B1, FABP3, FABP4, GBA2 | 3.45306 |
| [BP] GO:0007271 | None | CHRM1, CHRM2, CHRM3, CHRM5 | 3.44023 |
| [BP] GO:0010033 | response to organic substance | AKR1B1, ALPL, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, FABP4, HSD11B2, HSD17B2, MMP2, PPARA, TYR | 3.3424 |
| [BP] GO:0006694 | steroid biosynthetic process | AKR1B1, CYP19A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.28476 |
| [BP] GO:0009056 | catabolic process | ACHE, ADORA1, AKR1B10, AOX1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, FABP3, FABP4, FUT7, GBA2, MMP1, MMP2, MMP9, XDH | 3.2442 |
| [BP] GO:0044255 | cellular lipid metabolic process | ACHE, AKR1B10, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, FABP3, FABP4, FUT7, GBA2, PPARA | 3.12369 |
| [BP] GO:0048856 | anatomical structure development | ACHE, ADORA1, AKR1B1, ALPL, BCL2, CA2, CDK6, CHRM1, CHRM2, CHRM3, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, ESRRB, GBA2, HSD11B1, HSD17B2, MMP9, PPARA, TYR | 3.12369 |
| [BP] GO:0032502 | developmental process | ACHE, ADORA1, AKR1B1, ALPL, BCL2, CA2, CA9, CDC25B, CDK6, CHRM1, CHRM2, CHRM3, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, ESRRB, FABP4, FUT7, GBA2, HSD11B1, HSD17B2, MMP2, MMP9, PPARA, TNKS2, TYR | 3.12228 |
| [BP] GO:0007193 | None | ADORA1, CHRM1, CHRM2, CHRM3, CHRM5 | 3.11588 |
| [BP] GO:0097267 | omega-hydroxylase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 3.11167 |
| [BP] GO:0009719 | response to endogenous stimulus | AKR1B1, ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A2, ESR1, ESRRA, FABP3, HSD11B2, MMP2, PPARA | 3.07491 |
| [BP] GO:0048513 | animal organ development | ACHE, BCL2, CA2, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, ESR1, ESRRA, ESRRB, HSD11B1, HSD17B2, PPARA, TYR | 2.92333 |
| [BP] GO:0007200 | None | CHRM1, CHRM2, CHRM3, CHRM5, ESR1 | 2.87214 |
| [BP] GO:0006703 | estrogen biosynthetic process | CYP19A1, HSD17B1, HSD17B2 | 2.77273 |
| [BP] GO:0042221 | response to chemical | AKR1B1, ALPL, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, FABP4, HSD11B2, HSD17B2, MMP2, MMP9, PPARA, TYR | 2.69052 |
| [BP] GO:0009115 | None | AOX1, XDH | 2.69052 |
| [BP] GO:0042127 | regulation of cell proliferation | ADORA1, ADORA3, AKR1B1, BCL2, CDC25B, CDK6, CHRM1, CSNK2A1, CYP1B1, ESR1, ESRRA, F3, FABP3, MMP2, MMP9, XDH | 2.68735 |
| [BP] GO:0033559 | unsaturated fatty acid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 2.68735 |
| [BP] GO:0032501 | multicellular organismal process | ADORA1, AKR1B1, AKR1B10, ALPL, BCL2, CHRM1, CHRM3, CHRM5, CYP19A1, CYP1A2, CYP1B1, ESR1, ESRRB, F10, F3, FABP4, HSD11B2, HSD17B2, MMP1, MMP2, MMP9, PPARA, TNKS2, TYR | 2.67156 |
| [BP] GO:0010647 | positive regulation of cell communication | ADORA1, AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F10, F3, HCAR2, MMP9, PTPN1, TNKS, TNKS2, XDH | 2.66029 |
| [BP] GO:0023056 | positive regulation of signaling | ADORA1, AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F10, F3, HCAR2, MMP9, PTPN1, TNKS, TNKS2, XDH | 2.64215 |
| [BP] GO:0001676 | long-chain fatty acid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 2.64215 |
| [BP] GO:0006690 | icosanoid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 2.56376 |
| [BP] GO:0016137 | None | AKR1B1, AKR1B10, GBA2 | 2.39729 |
| [BP] GO:0044238 | primary metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CDC25B, CDK6, CHRM1, CHRM3, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, ESR1, ESR2, ESRRA, ESRRB, F10, F3, FABP3, FABP4, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MMP1, MMP2, MMP9, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 2.37536 |
| [BP] GO:0006631 | fatty acid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, FABP3, PPARA | 2.3436 |
| [BP] GO:1901615 | organic hydroxy compound metabolic process | AKR1B1, AKR1B10, BCL2, CYP19A1, CYP1A1, CYP1B1, GBA2, TYR | 2.33134 |
| [BP] GO:0008610 | lipid biosynthetic process | ACHE, AKR1B1, CSNK2A1, CYP19A1, CYP1A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 2.2893 |
| [BP] GO:0046110 | None | AOX1, XDH | 2.2893 |
| [BP] GO:0032849 | positive regulation of cellular pH reduction | CA2, CA7 | 2.2893 |
| [BP] GO:0048522 | positive regulation of cellular process | ACHE, ADORA1, AKR1B1, BCL2, CA2, CA7, CDC25B, CDK6, CHRM1, CSNK2A1, CYP19A1, CYP1A1, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F10, F3, FABP3, HCAR2, MMP1, MMP2, MMP9, PPARA, PTPN1, TNKS, TNKS2, XDH | 2.15572 |
| [BP] GO:0043401 | steroid hormone mediated signaling pathway | ESR1, ESR2, ESRRA, ESRRB, PPARA | 2.14822 |
| [BP] GO:0048518 | positive regulation of biological process | ACHE, ADORA1, AKR1B1, BCL2, CA2, CA7, CDC25B, CDK6, CHRM1, CHRM3, CSNK2A1, CYP19A1, CYP1A1, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F10, F3, FABP3, FABP4, HCAR2, MMP1, MMP2, MMP9, PPARA, PTPN1, TNKS, TNKS2, XDH | 2.14318 |
| [BP] GO:0006940 | None | ADORA1, CHRM1, CHRM2, CHRM3 | 2.14318 |
| [BP] GO:0009404 | toxin metabolic process | CYP1A1, CYP1A2, CYP1B1 | 2.1214 |
| [BP] GO:1903409 | reactive oxygen species biosynthetic process | CYP1A1, CYP1A2, CYP1B1 | 2.06833 |
| [BP] GO:0010035 | response to inorganic substance | AKR1B1, BCL2, CA2, CYP1A1, CYP1A2, CYP1B1, FABP4, MMP9 | 2.04523 |
| [BP] GO:0070213 | None | TNKS, TNKS2 | 2.04523 |
| [BP] GO:0006145 | None | AOX1, XDH | 2.04523 |
| [BP] GO:0018894 | dibenzo-p-dioxin metabolic process | CYP1A1, CYP1A2 | 2.04523 |
| [CC] GO:0031233 | None | CA4, F10, F3 | 2.2893 |
| [CC] GO:0005789 | endoplasmic reticulum membrane | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, GBA2, HSD11B1, HSD11B2, HSD17B2 | 2.04523 |
| [CC] GO:0044432 | endoplasmic reticulum part | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, F10, GBA2, HSD11B1, HSD11B2, HSD17B2, PTPN1 | 2.00317 |
| [CC] GO:0016323 | basolateral plasma membrane | ADORA1, CA2, CA4, CA9, CHRM3 | 1.58578 |
| [CC] GO:0032279 | None | CHRM2, CHRM3 | 1.5309 |
| [MF] GO:0004089 | carbonate dehydratase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 18.0214 |
| [MF] GO:0046914 | transition metal ion binding | AOX1, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, ESR1, ESR2, ESRRA, ESRRB, MMP1, MMP2, MMP9, PPARA, PTPN1, TNKS, TYR, XDH | 16.3268 |
| [MF] GO:0016836 | hydro-lyase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 11.6718 |
| [MF] GO:0016835 | carbon-oxygen lyase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 10.4139 |
| [MF] GO:0003824 | catalytic activity | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CDC25B, CDK6, CHRM1, CHRM3, CHRM5, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, F10, F3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MMP1, MMP2, MMP9, PTPN1, TNKS, TNKS2, TYR, XDH | 9.79705 |
| [MF] GO:0008270 | zinc ion binding | CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB, MMP1, MMP2, MMP9, PPARA, PTPN1, TNKS | 9.06567 |
| [MF] GO:0016712 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 6.82833 |
| [MF] GO:0016829 | lyase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 6.8276 |
| [MF] GO:0043169 | cation binding | ACHE, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CHRM3, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, ESR1, ESR2, ESRRA, ESRRB, F10, MMP1, MMP2, MMP9, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 6.61993 |
| [MF] GO:0016907 | None | CHRM1, CHRM2, CHRM3, CHRM5 | 6.47324 |
| [MF] GO:0043167 | ion binding | ACHE, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CDK6, CHRM3, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, ESR1, ESR2, ESRRA, ESRRB, F10, F3, FABP3, FABP4, HSD17B1, MMP1, MMP2, MMP9, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 6.23567 |
| [MF] GO:0016491 | oxidoreductase activity | AKR1B1, AKR1B10, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TYR, XDH | 5.94119 |
| [MF] GO:0046872 | metal ion binding | ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, ESR1, ESR2, ESRRA, ESRRB, F10, MMP1, MMP2, MMP9, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 5.5752 |
| [MF] GO:0016614 | oxidoreductase activity, acting on CH-OH group of donors | AKR1B1, AKR1B10, AOX1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, XDH | 5.42158 |
| [MF] GO:0070330 | aromatase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13 | 5.39207 |
| [MF] GO:0004497 | monooxygenase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, TYR | 5.15551 |
| [MF] GO:0005506 | iron ion binding | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, XDH | 4.95586 |
| [MF] GO:0005496 | steroid binding | ESR1, ESR2, ESRRA, ESRRB, HSD11B2, HSD17B1 | 4.07382 |
| [MF] GO:0019825 | oxygen binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13 | 4.05314 |
| [MF] GO:0015464 | None | CHRM1, CHRM2, CHRM3, CHRM5 | 4.05314 |
| [MF] GO:0098531 | transcription factor activity, direct ligand regulated sequence-specific DNA binding | ESR1, ESR2, ESRRA, ESRRB, PPARA | 3.89517 |
| [MF] GO:0004879 | nuclear receptor activity | ESR1, ESR2, ESRRA, ESRRB, PPARA | 3.89517 |
| [MF] GO:0016705 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, TYR | 3.89517 |
| [MF] GO:0003707 | steroid hormone receptor activity | ESR1, ESR2, ESRRA, ESRRB, PPARA | 3.53791 |
| [MF] GO:0048037 | cofactor binding | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, HSD11B2, HSD17B1, XDH | 3.44995 |
| [MF] GO:0033764 | steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.44023 |
| [MF] GO:0016616 | oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | AKR1B1, AKR1B10, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.40229 |
| [MF] GO:0016229 | steroid dehydrogenase activity | HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.3322 |
| [MF] GO:0004629 | None | ADORA1, CHRM1, CHRM3, CHRM5 | 3.28476 |
| [MF] GO:0020037 | heme binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 3.25162 |
| [MF] GO:0008395 | steroid hydroxylase activity | CYP19A1, CYP1A1, CYP2A13, CYP2A6 | 3.11167 |
| [MF] GO:0046906 | tetrapyrrole binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 3.11167 |
| [MF] GO:0008289 | lipid binding | ESR1, ESR2, ESRRA, ESRRB, F10, F3, FABP3, FABP4, HSD11B2, HSD17B1, PPARA | 3.10763 |
| [MF] GO:0099528 | None | CHRM1, CHRM2, CHRM3, CHRM5 | 2.93641 |
| [MF] GO:0016903 | None | AKR1B1, AKR1B10, AOX1, XDH | 2.69959 |
| [MF] GO:0038052 | RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | ESR1, ESR2 | 2.69052 |
| [MF] GO:0003845 | None | HSD11B1, HSD11B2 | 2.69052 |
| [MF] GO:0008389 | None | CYP2A13, CYP2A6 | 2.69052 |
| [MF] GO:0009055 | electron transfer activity | AKR1B1, AOX1, CYP19A1, CYP1A2, XDH | 2.48865 |
| [MF] GO:0008227 | None | CHRM1, CHRM2, CHRM3, CHRM5 | 2.33134 |
| [MF] GO:0016788 | None | ACHE, ADORA1, ALPL, CA1, CA2, CDC25B, CHRM1, CHRM3, CHRM5, PTPN1 | 2.04523 |
| [MF] GO:0034056 | estrogen response element binding | ESR1, ESR2 | 2.04523 |
KEGG Pathways Associated to Targeted Human Proteins
| KEGG Pathway ID | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|
| Nitrogen metabolism_Homo sapiens_hsa00910 | CA12, CA1, CA5B, CA5A, CA2, CA4, CA7, CA6, CA9, CA14 | 19.6838 |
| Steroid hormone biosynthesis_Homo sapiens_hsa00140 | HSD11B1, HSD11B2, HSD17B1, HSD17B2, CYP1A2, CYP1A1, CYP1B1, CYP19A1 | 9.7635 |
| Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | HSD11B1, CYP2A6, CYP2A13, CYP1A2, CYP1A1, CYP1B1 | 5.7765 |
| Ovarian steroidogenesis_Homo sapiens_hsa04913 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, CYP19A1 | 5.3601 |
| Cholinergic synapse_Homo sapiens_hsa04725 | CHRM2, ACHE, CHRM3, CHRM1, CHRM5, BCL2 | 5.0553 |
| Chemical carcinogenesis_Homo sapiens_hsa05204 | HSD11B1, CYP2A6, CYP2A13, CYP1A2, CYP1A1, CYP1B1 | 5.5964 |
| Metabolic pathways_Homo sapiens_hsa01100 | AKR1B1, TYR, GBA2, CYP19A1, HSD11B1, CYP2A6, FUT7, AKR1B10, HSD17B1, HSD17B2, CYP1A2, CYP1A1, AOX1, ALPL, XDH | 4.9876 |
| Tryptophan metabolism_Homo sapiens_hsa00380 | CYP1A2, CYP1A1, AOX1, CYP1B1 | 4.2992 |
| Retinol metabolism_Homo sapiens_hsa00830 | CYP2A6, CYP1A2, CYP1A1, AOX1 | 3.4973 |
| Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | CHRM2, CHRM3, CHRM1, ADORA3, CHRM5, ADORA1 | 3.022 |
| PPAR signaling pathway_Homo sapiens_hsa03320 | FABP3, FABP4, MMP1, PPARA | 3.4362 |
| Estrogen signaling pathway_Homo sapiens_hsa04915 | MMP2, MMP9, ESR1, ESR2 | 2.8962 |
| cAMP signaling pathway_Homo sapiens_hsa04024 | CHRM2, HCAR2, CHRM1, ADORA1, PPARA | 2.8256 |
| Bladder cancer_Homo sapiens_hsa05219 | MMP1, MMP2, MMP9 | 2.8395 |
| MicroRNAs in cancer_Homo sapiens_hsa05206 | CDK6, BCL2, CYP1B1, MMP9, CDC25B | 2.0916 |
| Calcium signaling pathway_Homo sapiens_hsa04020 | CHRM2, CHRM3, CHRM1, CHRM5 | 2.0584 |
| Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | CYP2A6, CYP1A2, AOX1 | 2.2296 |
| AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | MMP2, BCL2, F3 | 1.8523 |
| Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | CHRM2, CHRM3, CHRM1, CHRM5 | 1.8523 |
| Caffeine metabolism_Homo sapiens_hsa00232 | CYP2A6, CYP1A2, XDH | 5.3897 |
| Pathways in cancer_Homo sapiens_hsa05200 | CDK6, MMP1, MMP2, BCL2, MMP9 | 1.7486 |
| Sphingolipid signaling pathway_Homo sapiens_hsa04071 | ADORA3, BCL2, ADORA1 | 1.754 |
| Hepatitis B_Homo sapiens_hsa05161 | CDK6, BCL2, MMP9 | 1.5659 |
| PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | CHRM2, CDK6, CHRM1, BCL2 | 1.3324 |
| Proteoglycans in cancer_Homo sapiens_hsa05205 | MMP2, MMP9, ESR1 | 1.2872 |
| Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | FABP4, ADORA1 | 1.4431 |
| Prolactin signaling pathway_Homo sapiens_hsa04917 | ESR1, ESR2 | 1.2919 |
| Gastric acid secretion_Homo sapiens_hsa04971 | CHRM3, CA2 | 1.2919 |
| Glycerolipid metabolism_Homo sapiens_hsa00561 | AKR1B10, AKR1B1 | 1.4139 |
| Adherens junction_Homo sapiens_hsa04520 | PTPN1, CSNK2A1 | 1.2919 |
| Tyrosine metabolism_Homo sapiens_hsa00350 | AOX1, TYR | 1.754 |
| Small cell lung cancer_Homo sapiens_hsa05222 | CDK6, BCL2 | 1.2045 |
| Insulin resistance_Homo sapiens_hsa04931 | PTPN1, PPARA | 1.047 |
| Drug metabolism - other enzymes_Homo sapiens_hsa00983 | CYP2A6, XDH | 1.5781 |
| Galactose metabolism_Homo sapiens_hsa00052 | AKR1B10, AKR1B1 | 1.8377 |
| Complement and coagulation cascades_Homo sapiens_hsa04610 | F10, F3 | 1.2621 |
| NF-kappa B signaling pathway_Homo sapiens_hsa04064 | CSNK2A1, BCL2 | 1.1524 |
| Pancreatic secretion_Homo sapiens_hsa04972 | CHRM3, CA2 | 1.1376 |
| Measles_Homo sapiens_hsa05162 | CDK6, CSNK2A1 | 0.923 |
| Leukocyte transendothelial migration_Homo sapiens_hsa04670 | MMP2, MMP9 | 1.0048 |
| Cell cycle_Homo sapiens_hsa04110 | CDK6, CDC25B | 0.9759 |
| Jak-STAT signaling pathway_Homo sapiens_hsa04630 | BCL2, AOX1 | 0.8271 |
| Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | CA2, CA4 | 2.004 |
| Fructose and mannose metabolism_Homo sapiens_hsa00051 | AKR1B10, AKR1B1 | 1.8013 |
| cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | ADORA3, ADORA1 | 0.8196 |
| Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | AKR1B10, AKR1B1 | 1.754 |
| Epstein-Barr virus infection_Homo sapiens_hsa05169 | CSNK2A1, BCL2 | 0.7036 |
| Prostate cancer_Homo sapiens_hsa05215 | BCL2 | 0.534 |
| Taste transduction_Homo sapiens_hsa04742 | CHRM3 | 0.534 |
| MAPK signaling pathway_Homo sapiens_hsa04010 | CDC25B | 0.2952 |
| Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | CDC25B | 0.5167 |
| Apoptosis_Homo sapiens_hsa04210 | BCL2 | 0.4448 |
| TNF signaling pathway_Homo sapiens_hsa04668 | MMP9 | 0.4942 |
| Protein processing in endoplasmic reticulum_Homo sapiens_hsa04141 | BCL2 | 0.3976 |
| Insulin signaling pathway_Homo sapiens_hsa04910 | PTPN1 | 0.4448 |
| GnRH signaling pathway_Homo sapiens_hsa04912 | MMP2 | 0.534 |
| Hepatitis C_Homo sapiens_hsa05160 | PPARA | 0.4448 |
| Purine metabolism_Homo sapiens_hsa00230 | XDH | 0.3894 |
| Melanogenesis_Homo sapiens_hsa04916 | TYR | 0.5158 |
| Tight junction_Homo sapiens_hsa04530 | CSNK2A1 | 0.4448 |
| Viral carcinogenesis_Homo sapiens_hsa05203 | CDK6 | 0.3593 |
| Insulin secretion_Homo sapiens_hsa04911 | CHRM3 | 0.534 |
| Focal adhesion_Homo sapiens_hsa04510 | BCL2 | 0.3598 |
| Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | ESRRB | 0.4448 |
| Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | PPARA | 0.4322 |
| Ribosome biogenesis in eukaryotes_Homo sapiens_hsa03008 | CSNK2A1 | 0.534 |
| Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | BCL2 | 0.4347 |
| Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | ESR1 | 0.4782 |
| Neurotrophin signaling pathway_Homo sapiens_hsa04722 | BCL2 | 0.477 |
| Glucagon signaling pathway_Homo sapiens_hsa04922 | PPARA | 0.5158 |
| Wnt signaling pathway_Homo sapiens_hsa04310 | CSNK2A1 | 0.4448 |
| HIF-1 signaling pathway_Homo sapiens_hsa04066 | BCL2 | 0.5137 |
| Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | MMP9 | 0.3894 |
| Chronic myeloid leukemia_Homo sapiens_hsa05220 | CDK6 | 0.567 |
| Tuberculosis_Homo sapiens_hsa05152 | BCL2 | 0.3894 |
| Herpes simplex infection_Homo sapiens_hsa05168 | CSNK2A1 | 0.3846 |
| Glioma_Homo sapiens_hsa05214 | CDK6 | 0.5746 |
| Salivary secretion_Homo sapiens_hsa04970 | CHRM3 | 0.534 |
| Toxoplasmosis_Homo sapiens_hsa05145 | BCL2 | 0.4782 |
| Morphine addiction_Homo sapiens_hsa05032 | ADORA1 | 0.534 |
| Rheumatoid arthritis_Homo sapiens_hsa05323 | MMP1 | 0.534 |
| Melanoma_Homo sapiens_hsa05218 | CDK6 | 0.5717 |
| Pancreatic cancer_Homo sapiens_hsa05212 | CDK6 | 0.5746 |
| Glycerophospholipid metabolism_Homo sapiens_hsa00564 | ACHE | 0.523 |
| Peroxisome_Homo sapiens_hsa04146 | XDH | 0.534 |
| Adipocytokine signaling pathway_Homo sapiens_hsa04920 | PPARA | 0.5717 |
| Colorectal cancer_Homo sapiens_hsa05210 | BCL2 | 0.5791 |
| Renin secretion_Homo sapiens_hsa04924 | ADORA1 | 0.5746 |
| p53 signaling pathway_Homo sapiens_hsa04115 | CDK6 | 0.5717 |
| Bile secretion_Homo sapiens_hsa04976 | CA2 | 0.5717 |
| Non-small cell lung cancer_Homo sapiens_hsa05223 | CDK6 | 0.6126 |
| Endocrine and other factor-regulated calcium reabsorption_Homo sapiens_hsa04961 | ESR1 | 0.6617 |
| Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | BCL2 | 0.6432 |
| Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | AOX1 | 0.6605 |
| Sphingolipid metabolism_Homo sapiens_hsa00600 | GBA2 | 0.6617 |
| Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | HSD11B2 | 0.7151 |
| Linoleic acid metabolism_Homo sapiens_hsa00591 | CYP1A2 | 0.8196 |
| Other types of O-glycan biosynthesis_Homo sapiens_hsa00514 | FUT7 | 0.8022 |
| Nicotinate and nicotinamide metabolism_Homo sapiens_hsa00760 | AOX1 | 0.8196 |
| Glycosphingolipid biosynthesis - lacto and neolacto series_Homo sapiens_hsa00601 | FUT7 | 0.8271 |
| Collecting duct acid secretion_Homo sapiens_hsa04966 | CA2 | 0.8265 |
| Other glycan degradation_Homo sapiens_hsa00511 | GBA2 | 0.961 |
| Folate biosynthesis_Homo sapiens_hsa00790 | ALPL | 1.0386 |
| Vitamin B6 metabolism_Homo sapiens_hsa00750 | AOX1 | 1.2919 |
Target Exprsssion in Healthy Human Tissues (protein & mRNA level)
Protein expression data was from the "Human Proteome Map" datasetmRNA expression data was from the "GTEx" dataset
Average Target Expression (Fold Change) in Multiple Disease Conditions
Fold Change with Corresponding Normal SamplesClick each cell within the heatmap to access gene expression of individual patient samples